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Introduction
There is a need to define the goals of clinical care and
how the theory of such care is matched by the health
system and those working in it. The goals of clinical
care may seem self-evident, but it is only self-evident
if actions are directly matched to the best available
evidence for practice. Such considerations are especially
important at times of clinical transition, such as pre-
sentation to the emergency department, admission to
intensive care or discharge from an inpatient unit to
the community for the frail, those with complex and
multiple comorbidities, and those with life-limiting ill-
nesses. How can clinicians minimize iatrogenic harm
expectantly?
What are the Goals of Clinical Care?
In the early 1980s, Dr Eric Cassell wrote a seminal arti-
cle in the New England Journal of Medicine presenting
a very strong case that the key role in clinical care was
the relief of suffering1. The underlying need for Cassell
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to write the article was the perception that clinical
practice had or is at risk of moving away from this fun-
damental focus valued by patients, their families, and
the broader community. Reflection on current practice
suggests that, at times, clinicians still replace patient-
centered care with clinician-directed care without
always considering the individual person in his/her
current circumstance.
One can further characterize the goals of care in
terms of optimizing function, i.e., physical function,
emotional function, existential or spiritual function, so-
cial function, sexual function, and financial function.
Even this construct may not be sufficient to focus a wide
range of health practitioners providing care in disparate
settings to an individual. McCaffery et al.2, in a letter
to the Journal of Pain and Symptom Management, have
characterized the patient’s focus even more succinctly:
“Are you able to do the things that are important to
you?”. The goals of care, therefore, become optimizing
factors reflected by people with life-limiting illnesses
and their caregivers, such as the function and comfort
in each of the domains that are of significance to the
patient and that define the breadth of personhood3,4.
Miles Little, an hepatobiliary surgeon, challenges
clinicians in his book Humane Medicine, proposing
seven archetypal consultation types defined by whether
there are signs or symptoms, whether quality of life or
autonomy is threatened, and whether there are demon-
strable biomechanical abnormalities5. Clinical care is
very good for the treatment of acute medical, surgical,
obstetric and traumatic emergencies; however, one
could argue that clinical care responds poorly to some-
one with back pain with no objective signs or symptoms,
whose quality of life may be greatly impaired but has
no demonstrable biomechanical abnormalities on
imaging or pathologic testing. As such, when we think
about goals of care, we need to be aware of the very
great limitations in clinical practice that exist and will
continue to exist.
Optimizing physical function requires objective
measurement. The Australian-modified Karnofsky
Performance Status (AKPS) scale (100 indicates well,
and 0 indicates dead) correlates with prognosis as it
changes towards the end of life6. It also helps to predict
the need for additional supports; a Karnofsky of 70 is
the point at which people start to need additional
physical support.
The goals of care are focused around the person
with a life-limiting illness, defined in optimizing a
number of domains, all of which need to be measured
objectively if clinical care is going to realize the oppor-
tunities for improving outcomes for each individual
person who comes in contact with health services.
Times of Transition—An Opportunity 
to Reassess Health, Function and the 
Aims of Care
Any interaction with health professionals should be an
opportunity for patients to revisit the fundamental
goals of care. This is especially so for people whose
functional status is starting to become impaired, and
whose vulnerability to iatrogenic harm is greater. A per-
son starting to need additional care as their Karnofsky
falls below 70 is typically an older member of the com-
munity with increasing numbers of comorbid prob-
lems, medications for these conditions, and frailty with
a reduced ability to respond physiologically to rapid
changes in homeostasis (Figure 1).
In resource-rich countries, about 50% of people
will have warning of their deaths. Perversely, given
our improved health status translating into enhanced
life expectancy, the more likely we are to suffer from
chronic, progressive diseases and, therefore, have warn-
ing of our deaths. The majority of people are now dying
from progressive deterioration and chronic complex
illnesses rather than acute events in otherwise well
people. Such illnesses now include cancer, end-stage
organ failure, neurodegenerative diseases, and AIDS.
The typical trajectories of functional decline have
been codified into three major archetypal patterns:
progressive frailty, end-stage organ failure, and cancer7.
Frailty delivers a progressive decline in function with
no sudden changes. End-stage organ failure is charac-
terized by an overall decline punctuated at times by
acute-on-chronic deterioration (a saw-tooth pattern),
when recovery from each acute deterioration fails to
achieve the previous level of function before the epi-
sode of decompensation. The trajectory of cancer is one
of gradual decline with a precipitous acceleration in
decline in the last weeks or months of life.
Such predictable deterioration leads to a concept
of a “final common pathway”. Anorexia, weight loss and
fatigue in advanced diseases are the systemic manifes-
tations of the body's attempt to maintain homeosta-
sis. Unless the underlying cause can be reversed once
cachexia, with its inherent loss of lean body mass and
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catabolic destruction of muscle is established, the per-
son’s prognosis is predicted by the rate of systemic
decline. All three disease trajectories share these sys-
temic changes.
As people come into contact with the health sys-
tem, how effectively does the system (and those work-
ing in it) recognize: (1) the opportunity to optimize this
person’s function by minimizing any functional
decline throughout their contact with the health ser-
vice (especially as inpatients in hospital); and (2) where
people are systemically on their disease trajectory? For
example, in many hospitals around the world, people
still do not die. Instead, they have cardiac arrests where
resuscitation is unsuccessful. In such a model, death is
seen as a failure or adverse outcome rather than as an
inevitable outcome of systemic decline that had been
carefully, though unknowingly, documented in the
person’s clinical notes. Indeed, most of us have been
socialized through our clinical training to consider
death as the ultimate professional failure, yet rarely in
our health systems is death in this setting a result of
medical misadventure.
In the setting of deterioration, there needs to be a
distinction between futile treatment (where there are
potential value judgments) and clinically futile treat-
ment (where there are objective measures of outcomes
given a particular course of action)8. Clinically futile
treatment deals with objective outcomes. Such a
model requires a clear understanding of predictable
disease progression and the ideal response of clini-
cians and health systems to the person’s actual needs.
The other challenge in times of transition is that
every systemic insult is likely to have an irreversible
component. Once a person has entered that final com-
mon pathway, where nothing is going to substantially
change the course of their life-limiting illness, recovery
from any acute deterioration is unlikely to return to
the level of function before the insult. For many peo-
ple, such deterioration can be due to poorly managed
comorbid illnesses not adequately reviewed in the
context of the person’s systemic deterioration. As peo-
ple enter the final common pathway, it is important to
recognize the changes to metabolism for medications
as cachexia progresses. This applies for pre-existing
medications as well as medications added for symptom
control. Furthermore, increasing numbers of medica-
tions raise the risk of clinically significant drug interac-
tions and iatrogenic adverse events.
Given the three proposed trajectories of decline,
and that optimizing function is the key goal of care,
there is a clinical imperative to: (1) minimize insults
which may precipitate an acute deterioration in over-
all function; and (2) make every effort early to work
towards regaining the person’s previous functional
status when there is a sudden, reversible decline in
function.
In optimizing outcomes by maintaining better func-
tion, there is the potential to prolong the period during
which people have functional independence. Graphi-
cally, this could be considered as increasing the area
under the curve for functional independence (time
above AKPS, 70) while prognosis remains unchanged
(Figure 1). This model quantifies the goal of a better
maintained physical performance where the curve of
functional deterioration is shifted to the right, knowing
that a decline in function will predictably still occur.
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Figure 1. Better maintenance of functional physical independence for people experiencing a predictable decline in function
as part of a progressive illness by increasing the amount of time a person has an Australian-modified Karnofsky Status scale
score of >70 (dotted line) with identical prognoses.
A Framework for Prescribing as Functional
Status Declines (Figure 2)
Almost all prescribing in chronic complex disease is
built around commencing medications. Given the risks
of polypharmacy and the predictable systemic decline
in progressive illnesses that affects the pharmacody-
namics of medications, how do we predictably and
safely rationalize medications in these people?
As clinicians, are we simply waiting for side effects
such as postural hypotension to present because anti-
hypertensives have been continued despite extensive
weight loss, or symptomatic hypoglycemia to emerge
because glycemic agents have been continued despite
major changes in oral intake and body mass? Con-
versely, precipitously ceasing medications may be as
dangerous as continuing long-term medications for
inactive comorbid conditions.
Prescribing at the end of life
Data from a large randomized controlled trial of health
service delivery in palliative care had more than 460
people and their general practitioners participate from
the time of referral until death. A secondary analysis of
prescribing from that study demonstrated an increase
in the number of medications prescribed as death
approached because of the addition of medications
for symptom control with few reductions in medica-
tions for comorbid illnesses9. For the majority of peo-
ple, the total number of medications surpassed seven,
increasing the estimated likelihood of drug–drug inter-
actions to more than 80%10.
Another analysis of the same data showed an in-
crease in total anticholinergic load, closely mirroring
the increased use of medications for symptom control
(given their known anticholinergic activity). The absolute
number of medications did not peak until the week
before death. Given the need to focus on symptom
control at this time and hence an inability to decrease
these medications at the end of life, careful rationali-
zation of medication used for comorbid diseases will
minimize adverse effects and interactions with med-
ications required for symptom control.
What are the consequences of increasing the anti-
cholinergic load? Four levels of anticholinergic activity
have been attributed to every medication: (1) no known
anticholinergic activity; (2) potential anticholinergic
activity; (3) clinically significant anticholinergic effects,
which are sometimes seen; and (4) marked anticholinergic
effects11. Three significant findings from multifactor
analyses were noted for those with high anticholiner-
gic load: (1) performance status was diminished by 15%
over those with little or no anticholinergic load; (2)
global quality of life was significantly reduced; and (3)
increasing difficulty in concentration. Higher levels of
anticholinergic load are directly associated with three
key areas that impinge on one’s ability to “do the things
that are important”2.
How can prescribing be rationalized to reduce the
risk of iatrogenic harm from predictable effects of indi-
vidual medications or the cumulative effects of medi-
cations causing anticholinergic load?
A discussion on managing medications for comor-
bid conditions as end of life approaches covers topics
as diverse as hypertension, atrial fibrillation, diabetes,
hormone replacement therapy, opportunistic infection
prophylaxis, and immunosuppression following organ
transplantation. In all these clinical settings, there is a
need to work carefully with patients and their families
to ensure that as goals of care are revised and new
clinical targets developed, people understand the
rationale behind such decision making. For example,
someone with type II diabetes who has maintained
careful glycemic control over many years will need to
be supported as the target for glycemic control is
adjusted upwards, to account for loss of appetite, irregu-
lar eating at the end of life and potential steroid use to
avoid (rapidly fatal) hypoglycemia while avoiding an
episode of symptomatic hyperglycemia.
Characteristics of the illness—phase of care
There is an active assessment that each clinician see-
ing a patient for the first or 100th time needs to do. In
chronic complex or chronic progressive disease, there
are recognizable phases of care. Eagar et al.12 developed
the idea of “phase” from more than 30,000 encounters
between health professionals including nurses, doc-
tors and allied health practitioners, and patients to
define what now appears to be a simple and intuitive
model for people as the life-limiting illness progresses.
There are three phases, independent of diagnosis or
prognosis, on which it is important to focus in this dis-
cussion: stable; unstable; and deteriorating. Stable is rec-
ognized if functional status is unchanged over a period
of weeks to months. Unstable defines the person’s clin-
ical condition changing rapidly and unexpectedly—
a key transition point. Deteriorating describes the
changes seen in this person relating to the predictable
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Question 1
What phase of illness Terminal, Unstable Stable
is this person in? deteriorating
Question 2
What is the activity level of Inactive Active
Characteristics of
this comorbid illness?
the illness Question 3
Is the comorbid illness improved Yes No
by weight loss?
Question 4
What is the likely time to onset of Short Long
any increase in disease activity if
the medication is reduced?
Question 5
Are there changes in the pharmacokinetics Yes No
of the medication–absorption, 
volume of distribution (cachexia), 
Medication metabolism or excretion (worsening  
characteristics renal or hepatic function)?
Question 6
Is there a known withdrawal No Yes
syndrome from the medication?
Intent of
Question 7
prevention What is the level of prevention Primary Secondary Tertiary
being sought by the current therapy?
Question 8
Is the number needed to treat (NNT) high? Yes No
Question 9
Characteristics
Is the number needed to harm (NNH) low? Yes No
of risk Question 10
assessment Will the NNT to avoid a single event be Yes No
likely to increase with disease progression?
Question 11
Will the NNH to cause an adverse event Yes No
decrease with disease progression?
More likely to cease medication More likely to continue medication 
until further reassessment
Figure 2. Decision-making checklist for prescribing for comorbid conditions in people with chronic complex or chronic pro-
gressive illnesses—medication reduction, cessation or substitution.
and expected trajectory of their life-limiting illness.
The latter needs to be actively recognized by clinicians
especially at times of transition; and if a person’s pres-
entation is not clearly an “expected” deterioration, fur-
ther investigation is needed to determine the cause
for the changes leading to this clinical presentation.
It is most often when people become unstable that
they have contact with health services, and this is an
important opportunity to consider the appropriate
management and to review the overall goals of care.
The more acute the change, the more likely a cause will
be found. However, finding a cause does not necessar-
ily lead to treating that cause; this requires a careful
discussion with the patient in the context of his/her
life and their wishes at this time.
Even with an expected deterioration, there is the
question of prognostication. Five key global issues help
to inform a person’s prognosis: (1) the person’s life-
limiting illness; (2) their comorbid illness or illnesses;
(3) their response to disease-modifying treatment for
the life-limiting illness; (4) changes in systemic param-
eters (the final common pathway reflected in deterio-
rating functional status); and (5) the person’s own view
of their future.
A specific focus when someone presents with an
unexpected change in their overall condition and
function is for the health professional to ask whether a
medication caused the presentation? If not, does any
medication need to be modified to cope with the acute
changes? For instance, if this person is now hypoten-
sive, do their antihypertensive agents need to be ceased
at least in the short term and then reviewed once they
are stable? Is there a need for permanent reduction in
their medications to reduce the risk of future similar
adverse events?
Characteristics of the illness—comorbid diseases
affected by weight loss
Which medications or disease states will be most
affected by weight loss? Prior to the advent of antihy-
pertensive and hypoglycemic agents, people were
advised to lose weight as treatment for hypertension
and diabetes. The weight loss of chronic and malig-
nant disease appears to improve blood pressure and
glycemic control. However, weight loss in the cachectic
patient is predominantly muscle loss, which conversely
may worsen other chronic or comorbid illnesses such
as respiratory function in chronic obstructive airway
disease.
Medication issues—pharmacokinetics
Every facet of pharmacokinetics can be affected by the
changes experienced in progressive life-limiting ill-
nesses. Absorption can be affected by gut transit and
changes in the gut wall for orally administered medi-
cations. Volume of distribution will change with changes
in relative contributions of adipose tissue and muscle.
Both metabolic and excretory pathways may be affected
by worsening renal or hepatic function. Dose reduction
or substitution of another class of medication with the
same clinical benefit but an alternate metabolic path-
way may need to be considered for people who need
to stay on such a medication.
Medication issues—withdrawal
There may be explicit known withdrawal syndromes
that need to be carefully managed while the patient is
still well enough for downward titration of medica-
tions. This is done rather than abruptly terminating
them because of unacceptable side effects and further
toxicity associated with acute withdrawal13. Such care
requires careful continuous assessment of where this
person is on their disease trajectory.
Likely time course for recrudescence of an
inactive comorbid condition because of
medication reduction or cessation
If a medication dose is reduced or the medication
ceased, what is the time course to onset of symptoms
or disease? Is there simply a linear relationship between
time and risk, or is there a likelihood that an accelera-
tion of the underlying disease state may shorten the
time to symptom onset? Once diabetes has caused
end-organ damage, the changes are irreversible, but
the time course for this impairment is essentially lin-
ear for time and blood glucose levels, measured over
long periods of time.
Intent of prevention
It is imperative to know the original intent of a medi-
cation being prescribed. Primary prevention seeks to
avoid disease or modify risk. Secondary prevention
treats an asymptomatic state, and tertiary prevention
is to treat an established disease process. In these def-
initions of prevention, the same illness may require
identical treatments for differing levels of prevention.
For example, in hypertension, a person could require
treatment for secondary prevention (an asymptomatic
state) or an identical antihypertensive for tertiary 
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prevention because of evidence of end-organ dam-
age. Therefore, it is important to consider the indica-
tion for the treatment and, thus, relevance to therapy
in people with life-limiting illnesses.
Risk—numbers needed to treat or to harm
The other concept that underpins good prescribing,
especially in chronic complex or chronic progressive
illnesses, is the number needed to treat (NNT) (or
number needed to harm [NNH]) to deliver a clinical
benefit (or an adverse outcome). NNT is the inverse 
of the absolute risk reduction, and this allows us to
compare widely varying therapies in a very simple
way.
Linking NNT to prevention, the NNTs will be lower
for tertiary prevention than for primary prevention for
the same condition14. Within the context of people at
the end of life, NNT can be a tool to assist with ceasing
medications and, therefore, not simply commencing
medications for comorbid illnesses.
NNT and NNH deal with single medications and do
not consider the cumulative effects of several medi-
cations prescribed simultaneously for the same or
other comorbid illnesses. There is a need to consider
how to integrate concepts such as anticholinergic load 
and drug–drug interactions into a treatment–harm
equation.
The definitions of NNT and NNH have no time
courses associated with them. How many people need
to be treated for what length of time to avoid one
event? The number needed to treat (or harm) may not
be linear. Treating 100 people for 5 years may not be
the same as treating 500 people for 1 year, particularly
given the onset of action of a therapy, ceiling effects or
cumulative toxicity.
When time is factored into the calculation of NNT
or NNH, the NNT will rise for patients whose prognosis
is rapidly diminishing, and the NNH may well decrease
for a set benefit. At some point, toxicity of therapy may
well outweigh benefit as global function declines. The
therapeutic window (crudely considered as: NNT–NNH)
will narrow and may become negative for many fre-
quently encountered comorbid illnesses that have been
treated with stable doses of medication for years or
decades.
For each medication prescription renewed in hos-
pital or in the community, it is important to know the
aim of therapy, i.e., what was being prevented, partic-
ularly for comorbid conditions. This framework is as
important in chronic and complex conditions as in
care at the end of life. Such a framework may signifi-
cantly decrease the morbidity and, indeed potentially,
the mortality by better managing comorbid illness.
Palliative care can have premature mortality just as in
any clinical practice.
Implications for clinical practice
The population with chronic, complex or chronic pro-
gressive disease is at the above average risk for iatro-
genic harm. Medications that have been appropriate
and well tolerated earlier in a person’s life may cause
morbidity or even inadvertently hasten death without
careful review. Prognostication requires appreciation
of the natural history of life-limiting illnesses, the
impact of concurrent comorbid illnesses, and the rate
of change of function for individuals. Prescribing as
prognosis worsens requires careful consideration as
the benefit–harm balance shifts. Resetting goals of
care explicitly with patients and their families requires
explanation and negotiation.
Given the problems of multiple medications, which
can be worsened with multiple prescribers15, a single
coordinating clinician must be identified. This is espe-
cially difficult at times of transition in place of care as
this clinician may change. Careful consultation about
the original intent of a medication is crucial.
Optimizing compliance with medications that are
offering most benefit (or most harm if stopped abruptly)
is essential if unnecessary or premature deterioration
is to be avoided in a population with little reserve for
any iatrogenic insult. Compliance may also, at times, be
improved by considering alternative routes of admin-
istration for an existing medication.
Considered substitution of medications rather than
cessation may reduce toxicity of individual medica-
tions or the cumulative effects of medications taken in
combination (such as anticholinergic load). Judicious
dose reduction and continued careful review will allow
medications to be titrated accurately to minimize
harm.
Implications for research
A theoretical framework for understanding how to
adjust long-term medications already exists. Adding
high quality empirical evidence to the process will take
time. Early double-blind randomized controlled trials
exploring the withdrawal of long-term therapy provide
a crucial insight into a feasible and ethically acceptable
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method of defining the evidence base needed for
practice in this area16.
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